Literature DB >> 18208574

Higher optical density of an antigen assay predicts thrombosis in patients with heparin-induced thrombocytopenia.

Fevzi Altuntas1, Karen Matevosyan, James Burner, Yu-Min Shen, Ravindra Sarode.   

Abstract

OBJECTIVES: To correlate optical density and percent inhibition of a two-step heparin-induced thrombocytopenia (HIT) antigen assay with thrombosis; the assay utilizes reaction inhibition characteristics of a high heparin concentration. PATIENTS AND METHODS: Patients with more than 50% decrease in platelet count or thrombocytopenia (<150 x 10(9)/L) after exposure to heparin, who had a positive two-step antigen assay [optical density (OD) >0.4 and >50 inhibition with high concentration of heparin] were included in the study.
RESULTS: Forty of 94 HIT patients had thrombosis at diagnosis; 54/94 had isolated-HIT without thrombosis. Eight of the isolated-HIT patients developed thrombosis within the next 30 d; thus, a total of 48 patients had thrombosis at day 30. At diagnosis there was no significant difference in OD between HIT patients with thrombosis and those with isolated-HIT. However, OD was significantly higher in all patients with thrombosis (n = 48, 1.34 +/- 0.89), including isolated-HIT patients who later developed thrombosis within 30 d (n = 8, 1.84 +/- 0.64) as compared to isolated-HIT patients who did not develop thrombosis (0.96 +/- 0.75; P = 0.011 and P = 0.008). The Receiver Operative Characteristic Curve showed that OD >1.27 in the isolated-HIT group had a significantly higher chance of developing thrombosis by day 30. None of these groups showed significant difference in percent inhibition. Multivariate analysis showed a 2.8-fold increased risk of thrombosis in females. Similarly, thrombotic risk increased with age and OD values.
CONCLUSION: Higher OD is associated with significant risk of subsequent thrombosis in patients with isolated-HIT; percent inhibition, however, was not predictive.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18208574     DOI: 10.1111/j.1600-0609.2008.01035.x

Source DB:  PubMed          Journal:  Eur J Haematol        ISSN: 0902-4441            Impact factor:   2.997


  6 in total

Review 1.  Treatment and prevention of heparin-induced thrombocytopenia: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  Lori-Ann Linkins; Antonio L Dans; Lisa K Moores; Robert Bona; Bruce L Davidson; Sam Schulman; Mark Crowther
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

2.  Rapid exclusion or confirmation of heparin-induced thrombocytopenia: a single-center experience with 1,291 patients.

Authors:  Vanessa Nellen; Irmela Sulzer; Gabriela Barizzi; Bernhard Lämmle; Lorenzo Alberio
Journal:  Haematologica       Date:  2011-09-20       Impact factor: 9.941

3.  Consequences of treating false positive heparin-induced thrombocytopenia.

Authors:  Jacob Marler; Jessica Unzaga; Sundae Stelts; Carrie S Oliphant
Journal:  J Thromb Thrombolysis       Date:  2015-11       Impact factor: 2.300

4.  Pediatric heparin-induced thrombocytopenia: prevalence, thrombotic risk, and application of the 4Ts scoring system.

Authors:  Esther A Obeng; Kathy M Harney; Thomas Moniz; Alana Arnold; Ellis J Neufeld; Cameron C Trenor
Journal:  J Pediatr       Date:  2014-10-14       Impact factor: 4.406

Review 5.  Antithrombotic therapy in heparin-induced thrombocytopenia: guidelines translated for the clinician.

Authors:  Connie N Hess; Richard C Becker; John H Alexander; Renato D Lopes
Journal:  J Thromb Thrombolysis       Date:  2012-11       Impact factor: 2.300

6.  A comparison of direct thrombin inhibitors in the treatment of Heparin-Induced Thrombocytopenia: a single institution experience.

Authors:  Karen M Curzio; A Cheng-Lai; V Kheyfets; M Sinnet; H H Billett
Journal:  J Thromb Thrombolysis       Date:  2008-09-25       Impact factor: 2.300

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.